Willow is the most expensive provider here, and one of only two that posts its full price range rather than a starting figure. Publishing what the higher doses actually cost is unusual and genuinely useful — it lets you work out the real annual figure before you begin.
What the money buys is dosing craft. Custom 503A titration means increments are built for you rather than picked from a menu, and for anyone who has stopped a medication because the steps were too big, that is the thing that matters.
Here is how Willow reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
Two rows score strong here: dose fit and cost. Custom 503A preparation allows genuine individualisation of the dose, and the posted range means the cost row rates as well as it does — you can see the whole picture before committing, which is rarer on this page than it should be.
Willow positions itself as a medication provider rather than whole-woman care, and the scorecard reflects exactly that. There is no whole-person framing, no gynecologic context, no lasting-care plan — four rows at zero. At $399 you are paying a premium for dosing quality rather than breadth, which is a sound trade only if dosing is specifically what has gone wrong before.
Put these to Willow in writing, and keep the reply.
Willow does one thing genuinely well at a high price, and says so. The dosing craft and the published pricing are both real and both uncommon. It rates low on this Charter because it does not attempt the rest — and it is upfront that it does not.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.